Weimai Medical

What Weimai Medical does

Weimai Medical (微脉 / Weimai Technology Co., Ltd.) is a Hangzhou-headquartered digital health company founded in September 2015 that has built what it terms China's largest whole-disease course management (全病程管理) service platform. The company partners with city-level government health commissions and public hospitals to deploy an AI-powered platform that bridges in-hospital and post-discharge care, addressing the structural gap in continuous patient management in Chinese healthcare. Its core products include the CareAI health management intelligent application (formerly CareGPT, China's first health management LLM application, now integrated with DeepSeek, Qwen, and Baichuan Healthcare), the proprietary Neumann AI architecture powering virtual doctor assistants, knowledge graphs, and process automation, and the 凯琳·桑德 whole-disease course management methodology that integrates hospital EMR data with real-world data for digital therapeutics across 1,000+ disease management paths.

The business operates a B2B2C distribution model targeting three primary segments: government health authorities (city-level integrated healthcare platforms), public/private hospitals (internet hospital construction, AI butlers, whole-disease management), and healthcare providers/doctors (patient management tools, supplemental income generation), with patients reached through hospital deployments rather than direct consumer marketing. The company monetizes through multi-year hospital subscription contracts (typically 3-year terms with SLA-based service tiers), transaction fees on 20,000+ service SKUs enabled through the platform, insurance product distribution via its 2022-acquired national insurance brokerage, and licensing of its technology platform to city partners and other ecosystem participants. The platform covers 30 provinces, 280+ cities, 4,700+ public hospitals, and 200,000+ doctors, with 10 billion+ cumulative service users and 700,000+ daily active service users.

Weimai's competitive positioning rests on deep public hospital system integration rather than direct-to-consumer app competition, combined with a closed-loop 医-药-险 (medical-drug-insurance) service ecosystem enabled by the insurance brokerage acquisition. The company is recognized as a Zhejiang Province unicorn enterprise for four consecutive years (2022-2025), was named to CB Insights' Global Digital Health 150 in 2019 and 2020, and is the first Chinese company certified by the International Digital Therapeutics Alliance (DTA). Cumulative funding of approximately $300M USD equivalent has been raised from IDG Capital, Baidu Capital, 经纬中国, 千骥资本, 源码资本, 元璟资本, and most recently (January 2025) a 200M RMB Series D led by 信银投资 with multiple government-affiliated funds participating.

Name

Weimai Medical

Legal name

微脉技术有限公司

Website

https://myweimai.net

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Weimai Medical (微脉) is a Hangzhou-based digital health company that deploys an AI-powered whole-disease course management platform across 4,700+ public hospitals in 280+ Chinese cities, serving government health authorities, hospitals, doctors, and patients through B2B2C subscription contracts and closed-loop medical-drug-insurance services.

Ownership category

akta.pro rank

Product category

Digital Health Platform

NAICS

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518), General Medical and Surgical Hospitals (622110), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000), Services-Computer Processing & Data Preparation (7374)

akta.pro industry

PRIMARYHLACAIAB

Healthcare Master Data Management (MDM) & Patient/Provider Identity Data

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

SECONDARYHLACAIAF

Healthcare Terminology, Ontology & Code Set Management (SNOMED/LOINC/ICD/RxNorm)

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

SECONDARYHLACACAB

Claims Management, Scrubbing & Clearinghouse

Healthcare & Life Sciences/Digital Health & Health IT/Revenue Cycle Management (RCM) & Billing Software

SECONDARYHLAFAEAH

Hospital-at-Home / Acute Care at Home Programs

Healthcare & Life Sciences/Healthcare Providers & Systems/Home Health & Hospice Providers

Keywords

• Digital health platform
• Whole disease management
• AI healthcare solutions
• Hospital SaaS platform
• Internet hospital services

Headquarters

HQ city

Wuxi Shi

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Service Platform Fees (SLA/SKU-based): 微脉 generates revenue by providing hospitals with a full-stack AI+全病程管理 platform. Hospitals pay for licensed use of the platform and associated services. Revenue is derived from service fees based on the breadth of SLA (Service Level Agreement) and SKU (service packages) deployed per hospital. The platform enables hospitals to offer paid services (专病服务, 医护上门, etc.) with revenue sharing.
2. Hospital Service Increment Revenue Share: 微脉 helps hospitals create new paid service SKUs (e.g., specialist management packages, nursing home services, day surgery packages, maternity management). 微脉 takes a commission/transaction fee on the incremental service revenue generated through its platform, creating a usage-based/transaction revenue stream alongside the subscription component.
3. Insurance Integration (医-药-险闭环): Following the May 2022 acquisition of a national insurance brokerage company, 微脉 integrated insurance products into its healthcare service闭环. Revenue generated through insurance product distribution and brokerage fees.
4. Technology/Platform Licensing to Partners: 微脉 licenses its technology platform and AI tools (CareAI, Neumann AI, 全病程管理系统) to city partners, hospitals, and strategic partners, generating licensing and professional services revenue.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Weimai Medical operates an AI-powered whole disease course management platform that partners with government health authorities and public hospitals across China to deliver continuous patient care services from pre-admission through post-discharge. The platform combines the proprietary Neumann AI architecture and CareAI health management application with hospital information systems to enable digital therapeutics, AI consultations, report interpretation, and integrated care coordination across 4,700+ hospitals in 280+ cities. Revenue is generated through SLA-based subscriptions paid by hospitals, revenue shares on hospital service SKUs, technology licensing to city partners, and insurance brokerage commissions.

Product overview

Weimai Medical (威脉医疗/微脉) operates as a digital health company and AI+全病程管理 (whole disease management) pioneer. The company's platform integrates multiple products: the core CareAI健康管理智能应用 powered by Neumann AI architecture, the 互联网医院 platform for hospital digitalization, the 全病程管理系统 for continuous patient care, and specialized digital therapeutics for conditions like maternal health, chronic diseases, and rehabilitation. The company also developed the YOUMAGIC monopolar radiofrequency anti-aging device (separate product line). Services span appointment booking, telemedicine, AI-powered consultations, health records management, and specialized disease management across 32+ departments covering 1,000+ disease types with 20,000+ service SKUs.

Differentiator

Problem solved

Functional benefit

Brands

• CareAI: Proprietary AI-powered health management intelligent application developed by Weimai's Whole Disease Course Management AI Research Institute. It integrates deep learning, big data analysis, and natural language processing to build an intelligent service system covering disease prevention, health management, personalized diagnosis suggestions, and post-diagnosis disease management.
• CareGPT
• 微脉云谷中心

Products and services

• CareAI (formerly CareGPT) China's first AI-powered health management intelligent application developed by Weimai. Integrates 1 billion+ medical and case management data points, 500+ hospital patient management scenarios. Provides comprehensive health management services including disease prevention, AI consultation, report interpretation, AI doctor triage, AI psychological therapist, and post-diagnosis disease management. Trained on DeepSeek, Qwen, and Baichuan Medical foundation models.
• Whole Disease Process Management System (全病程管理系统) AI + whole disease course management platform covering pre-hospital, in-hospital, and post-hospital phases. Implements continuous closed-loop digital therapeutics through AI follow-up, home rehabilitation, online follow-up consultations, and guided secondary hospitalization. Supports 1,000+ disease management paths across specialties.
• Internet Hospital Solution (互联网医院) Comprehensive internet hospital solution integrating appointment registration, mobile payment, report inquiry, health consultation, health education, and prescription distribution. Connects hospitals, doctors, and patients for full-process smart medical services. Deployed across 4,700+ public hospitals.
• Digital Therapeutics Platform (数字疗法平台) Platform for digital therapeutics development and clinical validation. First Chinese company certified by the Digital Therapeutics Alliance (DTA) in April 2021. Covers 15+ disease management areas including hypertension, maternal health, child development, tumor screening, and chronic disease management.
• 恩泽AI健康管家 (AI Health Butler) Hospital-specific CareAI deployment built in collaboration with Taizhou Enze Medical Group. Features AI intelligent customer service, health consultation, report interpretation, AI doctor triage, AI psychological therapist, and AI medical assistant. Achieved 10,000+ daily service users with 98% patient satisfaction.
• 小红AI (Small Red AI Assistant) China's first obstetrics/gynecology emotion AI model co-developed with Fudan University Affiliated Obstetrics and Gynecology Hospital (Red House Hospital). Achieved >90% accuracy in clinical Q&A. First O&G vertical AI model in China, certified by Shanghai medical AI evaluation center. Powers the Red House Digital Innovation Alliance with 19 hospitals and 9 enterprises.
• YOUMAGIC A monopolar radiofrequency device for anti-aging treatments. Targets the high-end medical aesthetics device market with R&D and commercialization being accelerated through recent funding rounds.

Quantifiable outcome

• AI报告解读 accuracy: 93%, guiding 25% of patients to return for follow-up consultations (恩泽AI健康管家 data)
• +7 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature5 records

Partnerships

15 partnerships are on record, tiered major, flagship, core and minor.

• 西湖维泰majorStrategic or Co-development Partner · 1 December 2025战略合作协议 signed December 2025. Partnership focuses on integrating西湖维泰's precision diagnostics (mass spectrometry, genetic testing) with微脉's全病程管理 platform, targeting maternal-infant and chronic disease populations. Building '精准检测+智能管理+个性化干预'闭环.
• 复旦大学附属妇产科医院 (红房子医院)flagshipStrategic or Co-development Partner · 1 September 2025微脉 and 红房子医院 co-developed '小红AI助理', China's first obstetrics/gynecology emotion AI model. The partnership also established the first O&G Digital Innovation Alliance (红房子数智创新联盟) with 19 hospitals and 9 enterprises. '小红AI' achieved >90% accuracy and passed Shanghai's medical AI evaluation.
• 浙江省台州恩泽医疗中心(集团)flagshipStrategic or Co-development Partner · 1 April 2025恩泽医疗集团 and 微脉 jointly developed '恩泽AI健康管家' based on CareAI, deploying AI agents across all 5 hospital campuses. This is the first public hospital membership center in China. The partnership produces measurable results: 10,000+ daily AI services, 98% satisfaction, and serves as a flagship case for all 微脉 hospital deployments.
• 浙江省全病程管理人工智能企业研究院 (Internal R&D)coreOthers · 1 April 2025微脉's proprietary research institute (certified by浙江省经信厅) collaborates with浙江大学, 北京协和医学院 and other institutions on AI research, clinical validation, and talent development. Focus areas: AI agents, disease management paths, and digital therapeutics.
• DeepSeekcoreTechnology or Integration · 1 February 2025微脉 integrated DeepSeek as a core AI model foundation alongside 通义千问, 百川医疗, etc. DeepSeek powers CareAI's reasoning capabilities, enhancing AI report interpretation, health Q&A, and clinical decision support.
• 阿里云coreTechnology or Integration · 1 August 2024微脉 announced official cooperation agreement with阿里云 (signed August 2025). CareAI integrates通义千问 (Qwen) as a foundational AI model. Alibaba Cloud provides cloud infrastructure and AI model capabilities.
• 全国性保险经纪公司 (Acquired)coreOthers · 1 May 2022微脉 acquired a national insurance brokerage company in May 2022 to establish the '医、药、险' (medical-drug-insurance) service闭环. This enables微脉 to offer insurance products alongside medical services, creating a full-cycle managed care model.
• 海南自贸港生态软件园minorStrategic or Co-development Partner · 1 November 2021微脉 signed an agreement with Hainan Free Trade Port Ecological Software Park to jointly build a complete digital therapeutics industry chain, leveraging Hainan's policy advantages.
• 中国医院协会 & 清华大学医院管理研究院 & 北京协和医学院培训中心flagshipStrategic or Co-development Partner · 1 August 2021微脉 serves as the sole technical partner for the national课题 '《互联网+全病程管理与AI数字疗法》', jointly initiated with China Hospital Association, Tsinghua University Hospital Management Research Institute, and Peking Union Medical College. Over 100 hospitals participate as research sites.
• 中华慈善总会majorStrategic or Co-development Partner · 1 July 2021微脉 signed the '百院e网' donation project with中华慈善总会, donating internet hospital platforms and AI follow-up systems to 100 tertiary public hospitals free of charge, including operational training.
• 国际数字疗法协会 (DTA)coreStrategic or Co-development Partner · 1 April 2021微脉 became the first Chinese company certified by the Digital Therapeutics Alliance (DTA) in April 2021, after passing academic review by the DTA Academic Committee. 微脉 co-published《数字疗法价值评估及整合应用指南》with DTA.
• 中国妇幼健康信联体 & 中国信息协会医疗卫生和健康产业分会majorStrategic or Co-development Partner · 1 October 2020联合发起「全国改善妇幼服务行动计划」, aiming to assist 100+ maternal-child hospitals in service innovation through互联网+全病程管理. 微脉 provides technology and operational support.
• 国家卫生健康委医院管理研究所flagshipStrategic or Co-development Partner · 1 August 2020微脉 is the sole technical partner for the national课题 '全国互联网医院运营与管理现状调查及人才培养', initiated by NHIMA. This is a national-level research project that positions微脉 as the standard-bearer for internet hospital operations.
• 浙江省医疗健康集团 (浙医健)majorStrategic or Co-development Partner · 1 April 2020浙江省旅游集团's healthcare subsidiary (浙医健) partnered with微脉 to build operated internet hospitals in 4 hospitals (浙医健衢州医院, 浙医健杭州医院, 浙医健长兴医院, 浙医健开化医院). Focus on basic service upgrades and专科 innovation运营.
• 20+ Banks & 10+ Insurance CompaniesminorGTM or Marketing Partner · 1 January 2020Banks (浙江农信, 民生银行, 中国银行, etc.) and insurance companies (平安产险, 大象保险, etc.) partnered with微脉 to offer免费义诊 services to their customers during COVID-19. Created a joint COVID-19 prevention platform reaching 76万+ users.

Scale indicators10 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• WeDoctor (微医): Closest direct peer: WeDoctor operates an internet hospital platform serving public hospitals and patients across China with similar AI-assisted consultation, appointment, and chronic-disease management. Both pursue government health commission partnerships and B2B2C hospital deployment models; Weimai differentiates on whole-disease-course management depth while WeDoctor is broader in consumer reach.
• JD Health (京东健康): Major Chinese internet healthcare platform combining online pharmacy, telemedicine, and consumer health. Comparable in serving hospitals and patients via digital channels; competes with Weimai on AI consultation and chronic-disease management, with a stronger pharmaceutical supply chain.
• Alibaba Health (阿里健康): Alibaba's healthcare arm operating internet hospitals, pharmaceutical e-commerce, and AI medical services. Comparable in deploying AI medical agents integrated with foundation models (Qwen) and serving public hospitals; much larger capital base but more consumer-pharmacy oriented than Weimai's clinical-management focus.
• Ping An Healthcare and Technology (平安好医生): Ping An's internet healthcare platform combining AI consultation, hospital network, and insurance integration. Directly comparable to Weimai's insurance-brokerage-anchored managed-care model and serves overlapping hospital and patient segments in China.
• Chunyu Doctor (春雨医生): One of China's earliest mobile medical consultation platforms connecting doctors and patients. Comparable in AI-assisted consultation and chronic-disease management, though more consumer-app-centric and less embedded in hospital workflows than Weimai.
• Dingxiang Doctor (丁香医生): DXY's consumer and professional healthcare platform with strong doctor community and AI triage tools. Comparable in serving doctors and patients with digital tools; differs by being content/community-led rather than hospital-embedded like Weimai.

Emerging players

• Medlinker (医联): Chinese physician-focused platform for chronic disease management and continuing education. Partial overlap with Weimai's doctor-side tools and chronic-disease management paths, though narrower in hospital-deployment scale.
• Yidu Tech (医渡科技): Chinese healthcare AI company focused on medical data analytics, hospital decision support, and population health. Comparable in building AI on hospital EMR data and serving government/public-hospital customers; more analytics-oriented, less consumer-facing than Weimai.

Broad incumbents

• Tencent Health (腾讯健康): Tencent's broad healthcare initiative integrating AI, hospital partnerships, and consumer health within WeChat ecosystem. Overlaps with Weimai's WeChat-based distribution and AI medical agents; a potential competitor and platform partner simultaneously.
• Baidu Health (百度健康): Baidu's healthcare platform combining AI consultation, content, and pharmaceutical services, and a strategic capital partner of Weimai via Baidu Capital. Comparable in deploying AI medical assistants integrated with public hospitals but more consumer-search oriented.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/weimai5

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds10 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weimai Medical